The kinetic properties of sodium-proton exchange are abnormal in human red blood cells of hypertensive patients and it has been demonstrated that the transport protein undergoes post-translational modifications able to affect its kinetic properties. Protein kinase C (PKC) activation decreases the affinity constant for intracellular protons while insulin increases the maximal rate of proton translocation. The present study therefore aimed to examine the relationships among PKC activity, fasting insulin levels and the kinetic behaviour of sodiumproton exchange in red blood cells from 20 normotensives and 36 hypertensives.
Introduction
The Na ϩ /H ϩ exchange (NHE) is a function of ubiquitous membrane transport proteins that plays a key role in the regulation of cellular pH (pH i ), cellular volume and cell proliferation of all eukariotic cells. 1 The activity of the NHE is increased in different cell types in hypertensive patients, suggesting that its abnormal function may be involved in the pathophysiology of hypertension (for a review, see reference 2).
Previous studies on the kinetic properties of NHE in human red blood cells (RBC) from hypertensive patients have shown that, in comparison with normotensive subjects, the maximal velocity of translocation (V max ) is elevated and the Hill's coefficient with 1 mol/L phorbol 12-myristate 13-acetate (PMA) for 10 min, membrane PKC activity was stimulated to a larger extent in hypertensives (to 181 ؎ 8 pmol/min/mg protein) than in normotensives (to 136 ؎ 6 pmol/min/mg protein, P Ͻ 0.01). The PMA stimulated PKC activity was positively correlated to fasting insulin levels (r ‫؍‬ 0.59, P Ͻ 0.01).
Stimulation of membrane PKC by PMA corrected the low Hill's coefficient for H؉ i activation of sodium-proton exchange in the hypertensives, while the constant for half maximal activation for intracellular protons (ie, the affinity for intracellular protons) decreased to a similar extent in both groups. The maximal transport rate was unaffected by PMA.
These results indicate that the abnormal proton activation of red blood cell sodium-proton exchange in hypertensives reflects an abnormal regulation of PKC translocation to the cell membrane, associated to hyperinsulinaemia and probably insulin resistance. Therefore, post-translational modifications of the transport protein(s) account for the altered kinetic behaviour of sodium-proton exchange in hypertensives.
for H ϩ i activation is decreased, indicating a reduced number of cooperating binding sites for protons. 3 The kinetic abnormalities are more pronounced in insulin resistant hypertensives. 4 Similar kinetic alterations were found in vascular smooth muscle cells from spontaneously hypertensive rats (SHR). 5 These abnormalities are conserved in Epstein-Barr virus immortalised lymphoblasts from patients with essential hypertension, 6 suggesting that they are not due to the hypertensive milieu. The abnormal activation of the transporter in hypertension is not due to gene overexpression 7 and might be caused by a post-translational modification of NHE protein, such as phosphorylation. 8 Several hormones (ie, insulin, angiotensin II, endothelin I) and growth factors (ie, EGF, PDGF, thrombin) induce a marked increase of NHE phosphorylation accompanied by enhancement of the exchanger activity. 9, 10 The increase of NHE activity may be secondary either to reduced apparent K m (ie, increased affinity) for intracellular protons, or to increased number of transport units in the membrane or to increased turnover of the transport protein. The common signal transduction pathway for many agonists is the activation of phospholipase C, release of diacylglycerol (DAG) leading to activation of protein kinase C (PKC), 11 which is involved in the regulation of NHE (for a review, see reference 12). NHE can be modulated by different agonists also in RBC. The tumour-promoting drug, phorbol 12-myristate 13-acetate (PMA), a DAG replacing activator of PKC, decreases the affinity of NHE for intracellular protons (K m for H ϩ i ), without affecting V max in normotensives. 13 Moreover, immunoprecipitation studies of NHE-1, the NHE isoform which is expressed in RBC, have demonstrated that the transporter is phosphorylated by insulin 14 and that, in vitro, insulin increases V max of NHE. 15 PKC is a modulator of the insulin signalling chain and could be involved in the pathogenesis of cellular insulin resistance and the ensuing compensatory hyperinsulinaemia, a rather frequent finding commonly associated to essential hypertension. 16 Therefore, the abnormal kinetic properties of NHE in hypertensive patients could result from the combined effects of PKC activation and insulin.
The purpose of the present study was therefore to examine the interactions between PKC activation and insulin in RBC and their effects on the kinetic properties of NHE in RBC from hypertensives.
Patients and methods

Study population
Our laboratory has recently reported kinetic studies on NHE activation in normotensive healthy subjects and subjects with mild to moderate essential hypertension, who had been off any antihypertensive treatment for at least 4 weeks prior to the study. 17 From this population, we randomly selected 20 normo-insulinaemic normotensives and 36 hypertensives, to study the effects of PMA on NHE activation and on PKC activity of RBC membrane proteins. Their clinical characteristics are shown in Table 1 .
Measurement of NHE a) Preparation of RBC:
Blood was drawn into heparinized tubes and centrifuged at 3000 rpm for 4 min at 4°C. Plasma and buffy coat were removed by aspiration, and the RBC washed three times with b) Modification of cell cation content: The nystatin procedure was used to prepare sodium-depleted cells.
18 All solutions were prepared with deionized, double-distilled water, and the osmolarity was checked using a freezing point osmometer. Washed, packed cells were incubated at 15% hematocrit in cold nystatin loading solution (NLS) containing 40 g/ml nystatin for 20 min at 4°C and protected from light. Nystatin was dissolved in dimethyl sulfoxide (5 mg in 1.3 ml). For Na ϩ depletion, NLS contained (mmol/L): KCl 150, sucrose 50. The cell suspension was then warmed to 37°C for 5 min, and the red blood cells washed four times with warm nystatin washing solution (NWS). NWS had the same composition as the NLS with the pH adjusted to 7.4 with 1 mmol/L KH 2 PO 2 buffer and 10 mmol/L glucose and 0.1% albumin added. Removal of nystatin from the membrane was checked in every experiment by measurements of the passive permeability to Na ϩ .
c) Modification of RBC pH i :
Red blood cells with intracellular pH (pH i ) varying from 6.0 to 7.0 were prepared as previously described. 19 Briefly, Na ϩ -depleted cells (5% hematocrit) were incubated at 37°C for 10 min in six different acid-loading solutions, which contained (mmol/L): KCl 170, MgCl 2 0.15, ouabain 0.1, bumetanide 0.1 (prepared in dimethyl sulfoxide), glucose 10, and Tris-MES 20 adjusted to pH 5.8, 6.0, 6.1, 6.2, 6.4, 6.7 and 7 (ie, 1580, 1000, 790, 630, 400, 200 and 100 nmol/L) at 37°C. The osmolarity of the acid-loading solutions was adjusted to 360 mOsm by the addition of sucrose. After a 10-min preincubation with different acid-loading solutions, 100 mol/L 4,4-diisothiocyanato-stilbene-2,2-disulfonic acid (DIDS) (to inhibit the anion exchanger) and 200 mol/L neptazane (to inhibit carbonic anhydrase) were added to final concentrations of 100 and 200 mol/L, to clamp pH i .
The cells were incubated at 37°C for 20 more 
d) Measurement of net Na
؉ influx by NHE: NHE was estimated as net Na ϩ influx into Na ϩ depleted, acid loaded cells driven by an outward H ϩ gradient as previously reported. 19 To this end, initial rates of net Na ϩ influx were measured by incubating RBC in two different media, one with pH o 8.0 and another with pH o 6.0. The difference between both media determines the fraction of Na ϩ influx driven by an outward H ϩ gradient (ie, NHE). The experiment started with the addition of 200 l of a 50% suspension of the acid loaded cells to 2 ml Na ϩ influx media preincubated at 37°C in a shaking water bath. The Na ϩ influx media contained (mmol/L): NaCl 150, KCl 20, MgCl 2 0.15, ouabain 0.1, neptazane 0.4, glucose 10, sucrose 40, and either Tris-MOPS 10 (pH 8.0 at 37°C) or Tris-MES 10 (pH 6.0 at 37°C), 360 mOsm L. RBC of each different pH i were added to pH o 6.0 and pH o 8.0 Na ϩ influx media. At timed intervals (1, 6 and 11 min for pH o 8.0 and 1, 11, and 21 min for pH o 6.0) duplicate 250 l aliquots were pipetted into pre-cooled Eppendorf tubes containing 0.4 ml dibutylphthalate oil layered over 0.7 ml influx wash solution. The transport reaction was terminated by immediate centrifugation at 14 000 g for 10 sec at room temperature. The composition of the influx wash solution was (mmol/L): Choline chloride 80, KCl 80, MgCl 2 0.25, Tris-MOPS 10 (pH 7.4, at 4°C), and sucrose 40. The supernatant was carefully removed by aspiration and the external surface of the tubes wiped dry to eliminate Na ϩ contamination. The bottom of the tube, containing the cell pellet, was then cut off and placed into 1 ml of 0.02% Acationox to lyse the cells. The cell lysates were vortexed vigorously and centrifuged at 2000 g for 5 min at 4°C, and the haemoglobin concentration determined after diluting the lysate with 0.02% Acationox. The lysate Na ϩ concentration was determined by atomic absorption spectrophotometry and the cell Na ϩ content calculated by relating the optical density of the lysate to the hematocrit and optical density of the fresh cell suspension. Net Na ϩ influx was expressed as mmol/L per cell ϫ h. 
Measurement of PKC activity a) Preparation of red cell membranes and cytosol:
In 11 normotensives and 20 hypertensives, PKC activity was assayed at baseline and after PMA. Twenty ml of whole blood was centrifuged at 3000 rpm for 10 min at 4°C to remove plasma and buffy coat. . 20 After centrifugation at 18 000 rpm for 20 min, the supernatant (cytosol) was removed and stored on ice, and the ghosts washed three more times in hemolysis buffer B. Ghosts were resuspended to a final concentration of 1-2 mg of protein per ml of lysis buffer. b) Protein kinase C assay: Activity of PKC was assayed by measuring the rate of [ 32 P] phosphate incorporation from [␥ 32 P]ATP using saturating concentrations of a protein kinase C-selective peptide (EGF receptor, KRTLRLR). The standard assay mixture (final volume 75 l) contained 12 mmol/L calcium acetate, 30 mmol L DTT, 50 mmol/L Tris-HCl, 900 mol/L peptide, a detergent-dispersed solution of 20 g/ml L-phosphatidyl-L-serine and 24 g/ml PMA, [␥ 32 P]ATP (500 000 cpm/10 l). Cytosol fractions (300-400 g of protein) or membranes (20-50 g of protein) were added to this mixture. After 15 min of incubation at 25°C the reaction was stopped with 100 l of diluted trichloroacetic acid. A 125 l aliquot of the reaction media was spotted on a phosphocellulose paper (2.5 cm ϫ 2.5 cm). The paper was washed twice for 10 min, with stirring, in 5% v/v acetic acid, dried, and assayed for [ 32 P] by scintillation counting. PKC activity was expressed as picomoles of [␥ 32 P] incorporated into peptide per mg of protein per min. The protein concentration was measured by the method of Lowry et al 21 using bovine serum albumin as standard.
Statistical analysis
All the data were normally distributed except for fasting insulin levels, which were therefore logarithmically transformed. The statistical analysis was performed with Student's t-test for paired and unpaired data, univariate ANOVA and ANOVA with 
Results
As reported in Table 1 , hypertensive patients were comparable for age, but had a significantly higher blood pressure, body mass (BMI) and fasting insulin levels in comparison to normotensives. Figure 1 shows the activation curve of NHE of normotensive subjects and hypertensive patients. In agreement with previous reports, 3, 19 in normotensives NHE activity was sigmoidally stimulated by raising H ϩ i from 100 nmol/L (ie, pH 7) to 1000 nmol/L (ie, pH 6). On the contrary, in hypertensives, V max was not reached at pH i 6.0 (ie, H i 1000 nmol/L) and the activation curve by cell H ϩ showed less sigmoidicity (Hill's n 1.6 Ϯ 0.1), than in normotensives. The kinetic parameters are summarised in Table 2 . In comparison with normotensives, NHE of hypertensives exhibited a significant increase of V max (37.9 Ϯ 2.7 vs 27.6 Ϯ 1.9 mmol/L per cell h, P Ͻ 0.05) and a significant reduction of the Hill's coefficient (1.6 Ϯ 0.1 vs 2.0 Ϯ 0.1, P Ͻ 0.01), while the mean values K m for H ϩ i activation were similar in the two groups ( Table 2) . None of kinetic parameters of NHE was correlated to fasting insulin levels or BMI.
In resting cells, cytosolic PKC activity and membrane PKC activity were not significantly different in normotensive subjects and in hypertensive patients (3.7 Ϯ 0.3 vs 4.6 Ϯ 0.3 and 31.8 Ϯ 3.4 vs 36.2 Ϯ 2.9 pmol/min/mg protein, respectively) ( Figure 2 ). Membrane PKC activity markedly increased after treatment with 1 mol/L PMA for 10 min both in RBC of normotensives and hypertensive patients. However, PMA-stimulated PKC activity was significantly higher in the membranes from hypertensives than in normotensives (181.6 Ϯ 9.7 vs Figure 1 Kinetic of NHE activation by intracellular H + in normotensive control and in hypertensive patients. In normotensive (filled line), NHE was sigmoidally stimulated by raising intracellular H + (ie, by reducing cell pH i ). The maximal velocity (V max ) was 27.6 ± 1.9 mmol/L per cell × h (mean ± s.e.m.). K m for H + activation (ie, affinity) was 388 ± 33 nmol/L and Hill's n was 2.0 ± 0.1. In the hypertensive (dotted line), the kinetic parameters were: V max 37.9 ± 2.7 mmol/L per cell × h, K m 344 ± 33 nmol/L, Hill's n 1.6 ± 0.1. 135.9 Ϯ 6.3 pmol/min/mg protein, P Ͻ 0.01) ( Figure  2 ). PMA stimulated-membrane PKC activity was weakly but significantly correlated with fasting insulin levels (r = 0.59, P Ͻ 0.01) (Figure 3) .
In normotensive subjects, PMA increased the apparent affinity for H ϩ i (ie, reduced K m in comparison to basal values from 388 Ϯ 33 to 265 Ϯ 25 nmol/L, P Ͻ 0.01), while V max and Hill's coefficient did not change ( Figure 4 and Table 2 ). In hypertensives, PMA treatment decreased K m for H ϩ i activation (from 344 Ϯ 33 to 261 Ϯ 44 nmol/L, P Ͻ 0.01) and increased the Hill's coefficient (from 1.6 Ϯ 0.1 to 2.0 Ϯ 0.1, P Ͻ 0.01), while it did not change V max ( Figure 5 and Table 2 ). A 2 ϫ 2 ANOVA was conducted to evaluate the effects of basal Hill's n and diagnosis on the change of Hill's n induced by PMA. The mean and s.e.m. for all parameters at baseline and after PMA are reported in Table 2 . The results of ANOVA indicate a significant main effect of baseline Hill's n (P Ͻ 0.001), a borderline effect of diagnosis (P = 0.06) and a significant interaction of baseline Hill's n and diagnosis (P Ͻ 0.05). The same analysis was conducted for K m and indicated that PMA induces significant changes which were unrelated to diagnosis with no interactions.
Discussion
It has consistently been reported that the Hill's coefficient for H ϩ i activation of NHE is decreased in RBC of hypertensives while V max is increased. 3, 17, 22 The present study shows that PKC activation by PMA In normotensives NHE is stimulated by intracellular H ϩ in a sigmoidal manner, suggesting the existence of cooperating binding sites for H ϩ in the transport protein(s). When fitted to a Hill-type expression, NHE in RBC from normotensives is characterised by a Hill's coefficient of 2 or more. On the contrary, in hypertensives the activation of NHE by intracellular H ϩ shows less sigmoidicity, with a Hill coefficient lower than 2.
3 This implies that NHE activation in RBC of normotensives is highly sensitive to small variations in intracellular H ϩ , while in hypertensive patients the loss of cooperativity increases the velocity of proton translocation at near normal pH i . Although the underlying mechanisms leading to decreased Hill's coefficient in hypertensive patients are currently unknown, our observations suggest that they are most likely secondary to a defective regulation, possibly caused by intracellular factors.
The present report examined the effects of PKC and insulin on red blood cell NHE because, on one hand, the cytoplasmic domain of the NHE isoform expressed in the red blood cells (NHE-1) 14, 23 possesses a number of phosphorylation sites for serine/threonine kinases 12, 24 and, on the other end, phorbol esters, which stimulate PKC, activate the NHE exchanger in RBC. 13 Moreover, PKC affects intracellular insulin signalling chain 25 and it has been shown that is a potential cause of cellular insulin resistance and hyperinsulinaemia 16 and insulin increases NHE activity in vitro. , protein kinases, and G proteins which affect the signal transduction system and protein phosphorylation (for a review, see reference 12).
In the present study, in RBC from hypertensives PKC activation with PMA normalised the low Hill's coefficient while the effects on K m and V max were similar to those observed in normotensives. This was achieved through a larger PKC stimulation in hypertensives than in normotensives, suggesting that the abnormal H ϩ i activation observed in RBC NHE of hypertensives is specifically due to low PKC dependent phosphorylation.
Calpain is the enzyme responsible for the cleavage of membrane-associated PKC, a key step for PKC activation and degradation. 26 In comparison to normotensives, in hypertensives calpain is more active due to defective inhibition by calpastatin. 27 It is therefore reasonable that in the hypertensives excessive PKC stimulation by calpain is responsible for the large increase of PKC activity after PMA which can correct, at least acutely, the kinetic of H ϩ i activation of NHE by increasing the phosphorylation of the transport protein.
Insulin resistance and elevated circulating insulin are frequently found in hypertensive patients, even in the absence of obesity. 28 Insulin increases V max in vitro 15 and V max is increased in insulin-resistant hypertensives in comparison with insulin-sensitive patients. 4 In the present study, V max , BMI and circulating insulin were higher in hypertensives than in normotensives. Nevertheless, we did not find any correlation among fasting insulin levels, BMI and V max . Therefore we do not support the contention that the difference of V max between hypertensives and normotensives is secondary to hyperinsulinaemia, frequently found in insulin-resistant patients.
The PMA dependent PKC stimulation was significantly positively correlated to the prevailing plasma insulin levels in agreement with studies showing that PKC activation induces cellular insulin resistance and insulin hypersecretion. In fact, phorbol ester dependent PKC stimulation inhibits intracellular insulin signalling in vitro 29 and in pancreatic islet cell PMA stimulates insulin release and hyperinsulinaemia. 30 In summary, the present study shows that part of the abnormal kinetics of H ϩ i activation of RBC NHE in hypertensives are secondary to altered PKC regulation. In normotensives, the sigmoidal activation of Na ϩ influx through the NHE indicates that the transporter can be rapidly activated by changes of cell pH: on one hand, a fall of cell pH briskly stimulates Na ϩ influx and H ϩ efflux through the transporter; on the other hand an increase of cell pH inhibits the transporter and prevents further alkalinization. In hypertensives the low Hill's number indicates that the regulatory role of NHE is impaired and that the cell may be exposed both to excessive acidification or undue alkalinization with an ensuing abnormal regulation of cell volume and pH. The final effects are complex but they may contribute to the development of target organ damage of hypertensive patients.
